Loading clinical trials...

COMPLETEDPHASE1

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection

NCT03588923•Nanjing Sanhome Pharmaceutical, Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatitis C Virus infection.

Detailed Description

A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are 400, 600, and 800 mg.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose;
•18-65 years of age;
•Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50 kg for males and ≥45 kg for females;
•No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as Boceprevir, Telaprevir, Simeprevir, Sofosbuvir, Daclatasvir, Asunaprevir;
•No antiviral treatment such as immune modulators, thymosin or other immune stimulating factors, interferon, or Chinese herbs in the past 6 months;
•HCV RNA ≥10\*5 IU/mL at screening (Roche COBAS Taqman);
•Chronic genotype 1-6 HCV Infection;
•Serum ALT ≤10 times ULN;
•FibroScan score ≤17.5kPa within 6 months before screening or at screening, or absence of cirrhosis within 12 months before screening;
•Subjects are capable of understanding and complying with the protocol and have signed the informed consent form.

Exclusion Criteria

•Smoke more than 5 cigarettes per day within three months prior to screening;
•Subjects allergic to the study drug (including its excipients) or subjects who are prone to allergies;
•History of drug and/or alcohol abuse (alcohol consumption exceeding 14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);
•Blood donation or massive blood loss (\> 450 mL) within three months prior to screening;
•History of any non-HCV liver diseases, including but not limited to hemochromatosis, primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic hepatitis, non-alcoholic steatohepatitis, etc.;
•Subjects with dysphagia or with any gastrointestinal disorders (or postoperative conditions) that may affect the study drug absorption;
•Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
•Use of any drugs that alter liver enzyme activity within 28 days prior to screening;
•Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;
•Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the disposition of the study drug within 2 weeks prior to screening;
+13 more criteria

Locations (1)

Phase I Clinical Trial Unit, The First Hospital of Jilin University

Changchun, Jilin, China

Key Dates

Start Date

July 7, 2018

Primary Completion Date

August 10, 2018

Completion Date

August 10, 2018

Last Updated

August 28, 2018

Enrollment

ACTUAL participants

Conditions

HCV Infection

Interventions

SH229

DRUG

Placebos

DRUG

SH229

DRUG

Placebos

DRUG

SH229

DRUG

Placebos

DRUG

APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies

NCT05534633

HIV InfectionsHCV Infection+1 more

View study

COMPLETEDNA

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

NCT04134767

Substance UseHIV Infections+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

Inclusion Criteria

Exclusion Criteria

APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection